Dr. Ava Otoupalova co-led a landmark international study and Phase 3 clinical trial published in The Lancet EClinicalMedicine and The Lancet Infectious Diseases that identified tuberculosis as a major and previously underrecognized cause of deadly sepsis among people living with HIV. The ATLAS trial demonstrated that initiating anti-tuberculosis therapy immediately—before diagnostic confirmation—reduced mortality by 23%, effectively saving one in four patients. Conducted in collaboration with partners in Uganda and Tanzania, this work represents a major advance in global health and has significant implications for improving survival in regions heavily burdened by HIV, tuberculosis, and sepsis.